# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2023 Earnings Results

**Report date:** 2024-02-02 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2023

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.32%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.86 | N/A | +30.32% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the earnings beat on EPS. They emphasized their commitment to innovation and patient care.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on innovation and delivering value to patients.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance indicates effective cost management and profitability, despite the lack of revenue data. The stock's slight decline of 1.32% may reflect investor caution or profit-taking after the earnings announcement. Overall, the results suggest a solid financial position, but the absence of revenue details leaves some uncertainty.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2023_